Affibody and Agilent Technologies to Develop Robust Protein Sample
Affibody AB and Agilent Technologies Inc. announced a cooperative agreement to develop advanced protein sample preparation solutions for human biomarker discovery. Affibody will design and develop engineered Affibody® ligands for specific protein targets designated by Agilent, which Agilent plans to use to expand its line of proteomic sample preparation products. At the end of the development phase of the agreement, Affibody will supply Agilent with production quantities of the materials.
Under the agreement, Affibody will deliver highly specific and robust affinity capture ligands that will enable Agilent to expand its market-leading Multiple Affinity Removal System technology with new product configurations. These products will enable scientists involved in biomarker discovery from human serum/plasma to continue to dig deeper into the serum proteome, in order to discover and identify potential biomarkers that can be used for human disease diagnosis, monitoring of therapeutic intervention, and prognosis. The robustness of the Affibody® ligand permits unsurpassed reproducibility for sample-to-sample comparison, resulting in greater certainty and clarity of scientific data.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

The pangenome - key to new therapies - Genetic diversity opens up new ways to treat life-threatening diseases

New base at the heart of science and industry - LUMITOS AG now calls Germany's largest science and technology park in Berlin-Adlershof its home

Customized coating designs against resistant bacteria and viruses, including SARS-CoV-2 - Spartha Medical receives €2.4M in financing from European Innovation Council
Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis
Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic

Commercial Dishwashers Destroy Protective Layer in Gut - Chemical residue on clean plates

Poorly insulated nerve cells promote Alzheimer’s disease in old age - The results of the study show, for the first time, that defective myelin in the aging brain increases the risk of Aꞵ peptide deposition

How to repel mosquitoes with the right soap scent - Virginia Tech researchers conduct proof-of-concept study on mosquito’s scent preferences
